<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00495131</url>
  </required_header>
  <id_info>
    <org_study_id>200705080M</org_study_id>
    <nct_id>NCT00495131</nct_id>
  </id_info>
  <brief_title>Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-infected Patients</brief_title>
  <official_title>Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Genotype 1-infected Patients in Taiwan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <authority>Taiwan: Department of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic hepatitis C virus (HCV) infection is prevalent in the world, affecting 3% of the
      world's population. The current standard of therapy is pegylated interferon and ribavirin,
      reaching 54-63% of successful rates. In patients with HCV genotype 1 infection, a 48 week
      course of combination therapy has achieved a higher successful rate that a 24 weeks course
      of therapy. However, several studies in Taiwan have shown that a 24 week course of therapy
      has comparable or even better response to a 48 week course of therapy in Western countries.
      Therefore, whether a 48 week course of therapy can achieve a higher response to a 24 week
      course of therapy in Taiwanese patients with genotype 1 HCV infection remains unclear.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Combination therapy with interferon alfa (IFN-α) plus ribavirin for 24 to 48 weeks produces
      sustained virologic response (SVR) rate in approximately 31-47% of treatment naïve patients
      with chronic hepatitis C.(1-5) Patients with genotype 1 virus infection are less likely to
      have SVR that those with other genotypes infection, and therefore, patients infected with
      hepatitis C virus (HCV) genotype 1 should receive treatment for 48 weeks.(6) Recently,
      combination therapy with pegylated interferon alfa (pegylated IFN-α) plus ribavirin produces
      higher SVR rates (54-56%) than that with IFN-α plus ribavirin.(7,8) Furthermore, a large
      trial assessing the effect and duration of pegylated IFN-α plus ribavirin showed that the
      overall SVR rate was 63%. Among patients with genotype 1 HCV infection, standard dose
      ribavirin (1000 to 1200 mg per day) and 48 weeks of treatment were significantly more
      effective than low dose ribavirin (800 mg per day) or 24 weeks of treatment.(9) The SVR rate
      was 51% for genotype 1 patients receiving pegylated IFN-α plus standard dose ribavirin for
      48 weeks, whereas only 29% and 41% for those receiving pegylated IFN-α plus low dose
      ribavirin and standard dose ribavirin for 24 weeks, respectively. Based on these lines of
      evidence, 48 weeks of therapy with pegylated IFN-α (pegylated IFN-α 2a 180 μg or pegylated
      IFN-α 2b 1.5 μg per kilogram body weight weekly) plus ribavirin (1000 to 1200 mg per day) is
      recommended to treat patients with HCV genotype 1 infection.(10) In Taiwan, a multicenter
      study showed that a 6 month course treatment with pegylated IFN-α plus standard dose
      ribavirin had a comparable SVR rate to that with IFN-α plus standard dose ribavirin (67.1%
      versus 63.6%) in patients with chronic hepatitis C. Subgroup analysis showed that treatment
      with pegylated IFN-α plus standard dose ribavirin had a significantly higher SVR rate to
      that with IFN-α plus standard dose ribavirin (65.8% versus 41.0%) in patients with genotype
      1 HCV infection.(11) Recently, a pilot study comparing 24 and 48 weeks of pegylated IFN-α
      plus standard dose ribavirin in patients with genotype 1 HCV infection showed that 48 weeks
      of treatment is more efficacious that 24 weeks of treatment (SVR rate: 80.0% versus
      48.9%).(12) However, much difference of SVR rates occurred in these two studies, making
      optimal therapy in Taiwanese patients infected with genotype 1 HCV difficult to be
      determined. In the study, we aim to investigate in a large cohort whether 48 weeks treatment
      with pegylated IFN-α plus standard dose ribavirin is more efficacious than 24 weeks
      treatment in patients with genotype 1 HCV infection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Sustained Virologic Response</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Sustained Biochemical Response</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-related Withdrawal Rate</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histologic Response</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">308</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Peginterfron and ribavirin (24 weeks)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (&lt;75 kg, 1000 mg/day; &gt;= 75 kg, 1200 mg/day) for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peginterferon and ribavirin (48 weeks)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (&lt;75 kg, 1000 mg/day; &gt;= 75 kg, 1200 mg/day) for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated interferon alfa-2a plus ribavirin</intervention_name>
    <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (&lt;75 kg, 1000 mg/day; &gt;= 75 kg, 1200 mg/day) for 24 weeks</description>
    <arm_group_label>Peginterfron and ribavirin (24 weeks)</arm_group_label>
    <other_name>Pegasys plus Robatrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated interferon alfa-2a plus ribavirin</intervention_name>
    <description>Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (&lt;75 kg, 1000 mg/day; &gt;= 75 kg, 1200 mg/day) for 48 weeks</description>
    <arm_group_label>Peginterferon and ribavirin (48 weeks)</arm_group_label>
    <other_name>Pegasys plus Robatrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment naïve

          -  Age 18 and older than 18 years old

          -  Anti-HCV (Abbott HCV EIA 2.0, Abbott Diagnostic, Chicago, IL) positive &gt; 6 months

          -  Detectable serum quantitative HCV-RNA (Cobas Amplicor HCV Monitor v2.0, Roche
             Molecular Systems, Pleasanton, CA) with dynamic range 600~&lt;500,000 IU/ml

          -  HCV genotype 1 (Inno-LiPA HCV II, Innogenetics, Ghent, Belgium)

          -  Serum alanine aminotransferase levels above the upper limit of normal with 6 months
             of enrollment

          -  A liver biopsy consistent with the diagnosis of chronic hepatitis C

        Exclusion Criteria:

          -  Anemia (hemoglobin &lt; 13 gram per deciliter for men and &lt; 12 gram per deciliter for
             women)

          -  Neutropenia (neutrophil count &lt;1,500 per cubic milliliter)

          -  Thrombocytopenia (platelet &lt;90,000 per cubic milliliter)

          -  Co-infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

          -  Chronic alcohol abuse (daily consumption &gt; 20 gram per day)

          -  Decompensated liver disease (Child-Pugh class B or C)

          -  Serum creatinine level more than 1.5 times the upper limit of normal

          -  Autoimmune liver disease

          -  Neoplastic disease

          -  An organ transplant

          -  Immunosuppressive therapy

          -  Poorly controlled autoimmune diseases, pulmonary diseases, cardiac diseases,
             psychiatric diseases, neurological diseases, diabetes mellitus

          -  Evidence of drug abuse

          -  Unwilling to have contraception
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jia-Horng Kao, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ding-Shinn Chen, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ming-Yang Lai, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pei-Jer Chen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chun-Jen Liu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chen-Hua Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shih-Jer Hsu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hosptial, Yun-Lin Branch</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chih-Lin Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ren-Ai Branch, Taipei City Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cheng-Chao Liang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Far Eastern Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ching-Sheng Hsu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Buddhist Tzu Chi General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheng-Shun Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taichung Veterans General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital, Yun-Lin Branch</name>
      <address>
        <city>Douliou</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buddhist Tzu Chi General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ren-Ai Branch, Taipei Municipal Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998 Nov 19;339(21):1485-92.</citation>
    <PMID>9819446</PMID>
  </reference>
  <reference>
    <citation>Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998 Oct 31;352(9138):1426-32.</citation>
    <PMID>9807989</PMID>
  </reference>
  <reference>
    <citation>Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, Chu JS, Chen DS. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology. 1996 Nov;111(5):1307-12.</citation>
    <PMID>8898645</PMID>
  </reference>
  <reference>
    <citation>Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol. 1995;23 Suppl 2:8-12.</citation>
    <PMID>8720287</PMID>
  </reference>
  <reference>
    <citation>Reichard O, Norkrans G, Frydén A, Braconier JH, Sönnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet. 1998 Jan 10;351(9096):83-7.</citation>
    <PMID>9439491</PMID>
  </reference>
  <reference>
    <citation>EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol. 1999 May;30(5):956-61. Review.</citation>
    <PMID>10365827</PMID>
  </reference>
  <reference>
    <citation>Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001 Sep 22;358(9286):958-65.</citation>
    <PMID>11583749</PMID>
  </reference>
  <reference>
    <citation>Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep 26;347(13):975-82.</citation>
    <PMID>12324553</PMID>
  </reference>
  <reference>
    <citation>Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM; PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004 Mar 2;140(5):346-55.</citation>
    <PMID>14996676</PMID>
  </reference>
  <reference>
    <citation>National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002. Hepatology. 2002 Nov;36(5 Suppl 1):S3-20. Review.</citation>
    <PMID>12407572</PMID>
  </reference>
  <reference>
    <citation>Lee SD, Yu ML, Cheng PN, Lai MY, Chao YC, Hwang SJ, Chang WY, Chang TT, Hsieh TY, Liu CJ, Chen DS. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat. 2005 May;12(3):283-91.</citation>
    <PMID>15850469</PMID>
  </reference>
  <reference>
    <citation>Yu ML, Dai CY, Lin ZY, Lee LP, Hou NJ, Hsieh MY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL. A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. Liver Int. 2006 Feb;26(1):73-81.</citation>
    <PMID>16420512</PMID>
  </reference>
  <verification_date>September 2009</verification_date>
  <lastchanged_date>September 7, 2009</lastchanged_date>
  <firstreceived_date>June 29, 2007</firstreceived_date>
  <firstreceived_results_date>December 21, 2008</firstreceived_results_date>
  <responsible_party>
    <name_title>Dr. Jia-Horng Kao</name_title>
    <organization>National Taiwan University Hospital</organization>
  </responsible_party>
  <keyword>Chronic hepatitis C</keyword>
  <keyword>Genotype 1</keyword>
  <keyword>Interferon</keyword>
  <keyword>Ribavirin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
